{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:32:44Z","timestamp":1792787564954,"version":"4.5.0"},"reference-count":46,"publisher":"American Association for Cancer Research (AACR)","issue":"7","funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scholar Award","award":["RR160080"],"award-info":[{"award-number":["RR160080"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["CA070907"],"award-info":[{"award-number":["CA070907"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["1975-20190330"],"award-info":[{"award-number":["1975-20190330"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["CA070907"],"award-info":[{"award-number":["CA070907"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["CA213338"],"award-info":[{"award-number":["CA213338"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["CA213274"],"award-info":[{"award-number":["CA213274"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"name":"J.E. Johnson","award":["CA213338"],"award-info":[{"award-number":["CA213338"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Small cell lung cancer (SCLC) is a pulmonary neuroendocrine cancer with very poor prognosis and limited effective therapeutic options. Most patients are diagnosed at advanced stages, and the exact reason for the aggressive and metastatic phenotype of SCLC is completely unknown. Despite a high tumor mutational burden, responses to immune checkpoint blockade are minimal in patients with SCLC. This may reflect defects in immune surveillance. Here we illustrate that evading natural killer (NK) surveillance contributes to SCLC aggressiveness and metastasis, primarily through loss of NK-cell recognition of these tumors by reduction of NK-activating ligands (NKG2DL). SCLC primary tumors expressed very low level of NKG2DL mRNA and SCLC lines express little to no surface NKG2DL at the protein level. Chromatin immunoprecipitation sequencing showed NKG2DL loci in SCLC are inaccessible compared with NSCLC, with few H3K27Ac signals. Restoring NKG2DL in preclinical models suppressed tumor growth and metastasis in an NK cell\u2013dependent manner. Likewise, histone deacetylase inhibitor treatment induced NKG2DL expression and led to tumor suppression by inducing infiltration and activation of NK and T cells. Among all the common tumor types, SCLC and neuroblastoma were the lowest NKG2DL-expressing tumors, highlighting a lineage dependency of this phenotype. In conclusion, these data show that epigenetic silencing of NKG2DL results in a lack of stimulatory signals to engage and activate NK cells, highlighting the underlying immune avoidance of SCLC and neuroblastoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study discovers in SCLC and neuroblastoma impairment of an inherent mechanism of recognition of tumor cells by innate immunity and proposes that this mechanism can be reactivated to promote immune surveillance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-20-2808","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T11:00:57Z","timestamp":1611572457000},"page":"1813-1826","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis"],"prefix":"10.1158","volume":"81","author":[{"given":"Mingrui","family":"Zhu","sequence":"first","affiliation":[{"name":"1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas."},{"name":"2Simmons Comprehensive Cancer Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[{"name":"1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas."},{"name":"2Simmons Comprehensive Cancer Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Bender","sequence":"additional","affiliation":[{"name":"1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas."},{"name":"2Simmons Comprehensive Cancer Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Girard","sequence":"additional","affiliation":[{"name":"2Simmons Comprehensive Cancer Center, Dallas, Texas."},{"name":"3Hamon Center for Therapeutic Oncology Research University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Kollipara","sequence":"additional","affiliation":[{"name":"4McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buse","family":"Eglenen-Polat","sequence":"additional","affiliation":[{"name":"1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas."},{"name":"2Simmons Comprehensive Cancer Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Naito","sequence":"additional","affiliation":[{"name":"5Department of Respiratory Medicine and Clinical Immunology, Graduate School of medicine, Osaka University, Suita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha K.","family":"Savage","sequence":"additional","affiliation":[{"name":"6Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Huffman","sequence":"additional","affiliation":[{"name":"2Simmons Comprehensive Cancer Center, Dallas, Texas."},{"name":"3Hamon Center for Therapeutic Oncology Research University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Koyama","sequence":"additional","affiliation":[{"name":"5Department of Respiratory Medicine and Clinical Immunology, Graduate School of medicine, Osaka University, Suita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[{"name":"5Department of Respiratory Medicine and Clinical Immunology, Graduate School of medicine, Osaka University, Suita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7776-0767","authenticated-orcid":false,"given":"John D.","family":"Minna","sequence":"additional","affiliation":[{"name":"2Simmons Comprehensive Cancer Center, Dallas, Texas."},{"name":"3Hamon Center for Therapeutic Oncology Research University of Texas Southwestern Medical Center, Dallas, Texas."},{"name":"7Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas."},{"name":"8Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8605-2746","authenticated-orcid":false,"given":"Jane E.","family":"Johnson","sequence":"additional","affiliation":[{"name":"2Simmons Comprehensive Cancer Center, Dallas, Texas."},{"name":"6Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, Texas."},{"name":"7Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra A.","family":"Akbay","sequence":"additional","affiliation":[{"name":"1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas."},{"name":"2Simmons Comprehensive Cancer Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"key":"2022061706383661200_bib1","volume-title":"SEER Cancer Statistics Review, 1975\u20132017","author":"Howlader"},{"key":"2022061706383661200_bib2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrc.2017.106","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2022061706383661200_bib3","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.2147\/OTT.S204577","article-title":"Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges","volume":"12","author":"Regzedmaa","year":"2019","journal-title":"Onco Targets Ther"},{"key":"2022061706383661200_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"2022061706383661200_bib5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41568-019-0164-2","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2022061706383661200_bib6","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/ng.3899","article-title":"Neuroblastoma is composed of two super-enhancer-associated differentiation states","volume":"49","author":"van Groningen","year":"2017","journal-title":"Nat Genet"},{"key":"2022061706383661200_bib7","doi-asserted-by":"crossref","first-page":"5622","DOI":"10.1038\/s41467-019-13515-5","article-title":"ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"2022061706383661200_bib8","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1038\/ncomms7377","article-title":"RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer","volume":"6","author":"Niederst","year":"2015","journal-title":"Nat Commun"},{"key":"2022061706383661200_bib9","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jtho.2018.11.031","article-title":"Small cell lung cancer transformation as a mechanism of resistance to PD-1 therapy in KRAS-mutant lung adenocarcinoma: a report of two cases","volume":"14","author":"Iams","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2022061706383661200_bib10","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.21037\/tcr.2017.01.20","article-title":"Neuroendocrine differentiation in prostate cancer: key epigenetic players","volume":"6","author":"Gupta","year":"2017","journal-title":"Transl Cancer Res"},{"key":"2022061706383661200_bib11","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"2022061706383661200_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"2022061706383661200_bib13","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.21037\/jtd.2017.12.51","article-title":"Immune checkpoint inhibitors in small cell lung cancer","volume":"10","author":"Pakkala","year":"2018","journal-title":"J Thorac Dis"},{"key":"2022061706383661200_bib14","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.4049\/jimmunol.1600576","article-title":"Lung cancer subtypes generate unique immune responses","volume":"197","author":"Busch","year":"2016","journal-title":"J Immunol"},{"key":"2022061706383661200_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-0-12-800267-4.00003-1","article-title":"Recognition of tumors by the innate immune system and natural killer cells","volume":"122","author":"Marcus","year":"2014","journal-title":"Adv Immunol"},{"key":"2022061706383661200_bib16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cmet.2018.06.021","article-title":"Dysfunction of natural killer cells by FBP1-induced inhibition of glycolysis during lung cancer progression","volume":"28","author":"Cong","year":"2018","journal-title":"Cell Metab"},{"key":"2022061706383661200_bib17","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3389\/fimmu.2017.01061","article-title":"Potentiation of natural killer cells for cancer immunotherapy: a review of literature","volume":"8","author":"Lowry","year":"2017","journal-title":"Front Immunol"},{"key":"2022061706383661200_bib18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-immunol-032712-095951","article-title":"Regulation of ligands for the NKG2D activating receptor","volume":"31","author":"Raulet","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"2022061706383661200_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/35093109","article-title":"Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity","volume":"413","author":"Diefenbach","year":"2001","journal-title":"Nature"},{"key":"2022061706383661200_bib20","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2003-06-2125","article-title":"Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8(+) T cells","volume":"103","author":"Verneris","year":"2004","journal-title":"Blood"},{"key":"2022061706383661200_bib21","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1084\/jem.161.5.1135","article-title":"Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer","volume":"161","author":"Doyle","year":"1985","journal-title":"J Exp Med"},{"key":"2022061706383661200_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fimmu.2011.00018","article-title":"Natural killer cells: from basic research to treatments","volume":"2","author":"Vivier","year":"2011","journal-title":"Front Immunol"},{"key":"2022061706383661200_bib23","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.cell.2018.03.028","article-title":"Chemistry-first approach for nomination of personalized treatment in lung cancer","volume":"173","author":"McMillan","year":"2018","journal-title":"Cell"},{"key":"2022061706383661200_bib24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"2022061706383661200_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"2022061706383661200_bib26","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0711293105","article-title":"MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma","volume":"105","author":"Jinushi","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706383661200_bib27","first-page":"8996","article-title":"MICA\/NKG2D-mediated immunogene therapy of experimental gliomas","volume":"63","author":"Friese","year":"2003","journal-title":"Cancer Res"},{"key":"2022061706383661200_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1535-6108(03)00220-4","article-title":"Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model","volume":"4","author":"Meuwissen","year":"2003","journal-title":"Cancer Cell"},{"key":"2022061706383661200_bib29","doi-asserted-by":"crossref","first-page":"e26663","DOI":"10.4161\/onci.26663","article-title":"Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma","volume":"2","author":"Soriani","year":"2013","journal-title":"Oncoimmunology"},{"key":"2022061706383661200_bib30","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1158\/0008-5472.CAN-13-1703","article-title":"RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma","volume":"74","author":"Lam","year":"2014","journal-title":"Cancer Res"},{"key":"2022061706383661200_bib31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/tlcr.2017.10.07","article-title":"Transcriptional deregulation underlying the pathogenesis of small cell lung cancer","volume":"7","author":"Kim","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"2022061706383661200_bib32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2022061706383661200_bib33","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s41591-018-0116-5","article-title":"Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses","volume":"24","author":"Canadas","year":"2018","journal-title":"Nat Med"},{"key":"2022061706383661200_bib34","first-page":"545","article-title":"HDAC inhibitors suppressed small cell lung cancer cell growth and enhanced the suppressive effects of receptor-targeting cytotoxins via upregulating somatostatin receptor II","volume":"10","author":"Sun","year":"2018","journal-title":"Am J Transl Res"},{"key":"2022061706383661200_bib35","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1158\/0008-5472.CAN-18-0161","article-title":"NK cells mediate synergistic antitumor effects of combined inhibition of HDAC6 and BET in a SCLC preclinical model","volume":"78","author":"Liu","year":"2018","journal-title":"Cancer Res"},{"key":"2022061706383661200_bib36","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.molmed.2017.10.002","article-title":"Boosting natural killer cell-based immunotherapy with anticancer drugs: a perspective","volume":"23","author":"Cifaldi","year":"2017","journal-title":"Trends Mol Med"},{"key":"2022061706383661200_bib37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1189\/jlb.0711339","article-title":"Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression","volume":"91","author":"Rossi","year":"2012","journal-title":"J Leukoc Biol"},{"key":"2022061706383661200_bib38","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s11095-013-1231-0","article-title":"The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells","volume":"32","author":"Zhu","year":"2015","journal-title":"Pharm Res"},{"key":"2022061706383661200_bib39","doi-asserted-by":"crossref","first-page":"45266","DOI":"10.1038\/srep45266","article-title":"The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3","volume":"7","author":"Ni","year":"2017","journal-title":"Sci Rep"},{"key":"2022061706383661200_bib40","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nature01112","article-title":"Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation","volume":"419","author":"Groh","year":"2002","journal-title":"Nature"},{"key":"2022061706383661200_bib41","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4049\/jimmunol.175.2.720","article-title":"Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo","volume":"175","author":"Wiemann","year":"2005","journal-title":"J Immunol"},{"key":"2022061706383661200_bib42","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.aao0505","article-title":"Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity","volume":"359","author":"de Andrade","year":"2018","journal-title":"Science"},{"key":"2022061706383661200_bib43","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1158\/0008-5472.CAN-05-2520","article-title":"Proteolytic release of soluble UL16-binding protein 2 from tumor cells","volume":"66","author":"Waldhauer","year":"2006","journal-title":"Cancer Res"},{"key":"2022061706383661200_bib44","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1126\/science.1258867","article-title":"A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection","volume":"348","author":"Deng","year":"2015","journal-title":"Science"},{"key":"2022061706383661200_bib45","first-page":"52","article-title":"Small cell lung cancer transformation during immunotherapy with nivolumab: a case report","volume":"21","author":"Imakita T","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"2022061706383661200_bib46","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","article-title":"Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity","volume":"177","author":"Gauthier","year":"2019","journal-title":"Cell"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/81\/7\/1813\/3089230\/1813.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/81\/7\/1813\/3089230\/1813.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T16:33:09Z","timestamp":1655483589000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/81\/7\/1813\/670530\/Evasion-of-Innate-Immunity-Contributes-to-Small"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,1,25]]},"published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-20-2808","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22428834.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428831","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428837","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428831.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428837.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428828","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428834","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22428828.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6513162.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6513162","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,25]]}}}